BridgeBio Pharma, Inc. (BBIO) — Financial Health & SEC Filings | Sharpnel
BridgeBio Pharma, Inc. (BBIO)
Nasdaq · Common Stock · Pharmaceutical Preparations
One email a week from me: what it filed, which 13F holders added or cut, where its scores stand. Free.
company in Palo Alto, United States
Financial health
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
Piotroski F-score
2 / 8
FAILReturn on assets positiveROA -78.3%
FAILOperating cash flow positiveOCF -446M
FAILReturn on assets improving-59.1% → -78.3%
PASSCash flow exceeds earningsOCF -446M vs NI -733M
FAILLong-term debt ratio falling47.6% → 214.5% of assets
Bankruptcy-risk screen combining working capital, retained earnings, operating income, market value against liabilities, and asset turnover. Above 2.99 is the safe zone; below 1.81 is distress.
Cash conversion
60.8%
Share count change
2.9%
Six-year record
Year
Revenue
Net income
Free cash flow
Gross margin
Shares
FY2020
$8.2M
−$505.5M
−$407.2M
—
117,995,457
FY2021
$69.7M
−$586.5M
−$511.2M
—
144,356,619
FY2022
$77.6M
−$484.7M
−$424.3M
—
147,473,076
FY2023
$9.3M
−$653.3M
−$529.0M
—
162,791,511
FY2024
$221.9M
−$543.3M
−$521.7M
—
186,075,873
Ownership flow
16 institutions tracked — 7 added, 8 reduced, 1 opened a new position. Active managers added 2,530,163 shares while index money cut 4,558,556.
Institutional holders of BridgeBio Pharma, Inc. and their share-count change
Manager
Kind
Shares
Change
Value
BlackRock, Inc.
Index
10,287,156
−3,920,601
$766.2M
WELLINGTON MANAGEMENT GROUP LLP
Active fund
5,308,924
+2,824,971
$395.4M
PRICE T ROWE ASSOCIATES INC /MD/
Active fund
1,726,383
−2,075,272
$128.6M
VIKING GLOBAL INVESTORS LP
Hedge fund
9,949,219
Capital returned
What the company actually paid out and bought back, as reported — the record behind any yield figure.
Shares repurchased
2026Q1
$82.5M
2025Q1
$48.3M
2024Q1
$0
2021Q1
$50.0M
2020Q1
$75.0M
Identity
CIK
0001743881
LEI
54930028YG89VTY2J114
FIGI
BBG00P9KDZK6
SIC
2834 · Pharmaceutical Preparations
Incorporated
DE
Headquarters
PALO ALTO, CA
Founded
2015-01-01
Ownership
Institutional
100.6%
Institutions
660
Insiders
3.9%
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
BridgeBio Pharma, Inc. scores 2 out of 8 on the Piotroski F-score. Only 8 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Its Altman Z-score puts it in the distress zone. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.
Who are the largest institutional holders of BridgeBio Pharma, Inc.?
Among the managers tracked here, the biggest positions as of the 2026-Q3 13F filings are BlackRock, Inc. (trimming), VIKING GLOBAL INVESTORS LP (trimming), WELLINGTON MANAGEMENT GROUP LLP (adding). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.
This page is one panel of the terminal
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
FY2025
$502.1M
−$732.9M
−$447.0M
—
191,527,482
−1,893,215
$741.0M
Point72 Asset Management, L.P.
Hedge fund
1,532,782
+1,485,582
$114.2M
JPMORGAN CHASE & CO
Active fund
2,397,995
+1,081,336
$173.2M
CITADEL ADVISORS LLC
Hedge fund
4,326,928
+936,688
$322.3M
STATE STREET CORP
Index
4,435,932
−498,388
$330.4M
RENAISSANCE TECHNOLOGIES LLC
Hedge fund
856,846
+491,074
$63.8M
FMR LLC
Active fund
2,061,307
−282,447
$153.5M
Bridgewater Associates, LP
Hedge fund
448,143
+188,684
$33.4M
MORGAN STANLEY
Active fund
1,693,652
−183,707
$126.1M
GEODE CAPITAL MANAGEMENT, LLC
Index
3,278,852
−139,567
$215.8M
BANK OF AMERICA CORP /DE/
Active fund
1,235,380
−50,368
$92.0M
AQR CAPITAL MANAGEMENT LLC
Hedge fund
166,949
+6,837
$12.4M
NORGES BANK holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register. These filings span 2026-Q2–2026-Q3 rather than a single quarter, because filers report on their own schedules.